BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30223570)

  • 1. Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Koga F; Takemura K; Fukushima H
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer.
    Koga F; Yoshida S; Tatokoro M; Kawakami S; Fujii Y; Kumagai J; Neckers L; Kihara K
    PLoS One; 2011; 6(11):e27616. PubMed ID: 22102915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
    Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
    Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
    Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
    Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer.
    Yoshida S; Koga F; Kobayashi S; Ishii C; Tanaka H; Tanaka H; Komai Y; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e21-7. PubMed ID: 22414281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer.
    Mitin T; Choudhury A
    World J Urol; 2019 Sep; 37(9):1767-1772. PubMed ID: 30218307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer.
    Gray PJ; Shipley WU; Efstathiou JA; Zietman AL
    Curr Opin Urol; 2013 Sep; 23(5):429-34. PubMed ID: 23851382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.
    Coen JJ; Paly JJ; Niemierko A; Kaufman DS; Heney NM; Spiegel DY; Efstathiou JA; Zietman AL; Shipley WU
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):311-6. PubMed ID: 23474117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions.
    Aragon-Ching JB; Werntz RP; Zietman AL; Steinberg GD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():307-318. PubMed ID: 30231340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of radical cystectomy in potential candidates for bladder preservation therapy.
    Pietzak EJ; Sterling ME; Smith ZL; Malkowicz SB; Guzzo TJ
    Urology; 2015 Apr; 85(4):869-75. PubMed ID: 25681831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
    Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy.
    Tanaka H; Yoshida S; Koga F; Toda K; Yoshimura R; Nakajima Y; Sugawara E; Akashi T; Waseda Y; Inoue M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1408-1416. PubMed ID: 29960059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.
    El-Taji OM; Alam S; Hussain SA
    Curr Treat Options Oncol; 2016 Mar; 17(3):15. PubMed ID: 26942590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
    Rose TL; Deal AM; Ladoire S; Créhange G; Galsky MD; Rosenberg JE; Bellmunt J; Wimalasingham A; Wong YN; Harshman LC; Chowdhury S; Niegisch G; Liontos M; Yu EY; Pal SK; Chen RC; Wang AZ; Nielsen ME; Smith AB; Milowsky MI;
    Bladder Cancer; 2016 Oct; 2(4):405-413. PubMed ID: 28035321
    [No Abstract]   [Full Text] [Related]  

  • 19. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
    El-Achkar A; Souhami L; Kassouf W
    Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.